Genenta Science S.p.A (GNTA) Long-Term Deferred Tax (2020 - 2022)
Genenta Science S.p.A (GNTA) posted Long-Term Deferred Tax of $9.9 million for Q4 2022, up 15.85% sequentially from $8.5 million in Q4 2021, and up 15.85% YoY from $8.5 million in Q4 2021.
Genenta Science S.p.A (GNTA) Long-Term Deferred Tax (2020 - 2022) Analysis & Trends
Genenta Science S.p.A has reported Long-Term Deferred Tax for 3 years, with the latest figure at $9.9 million in Q4 2022.
- Quarterly Long-Term Deferred Tax rose 15.85% year-over-year to $9.9 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $9.9 million (up 15.85% YoY) and the FY2022 annual result came in at $9.9 million, up 15.85% from the prior year.
- Long-Term Deferred Tax advanced to $9.9 million in Q4 2022 per GNTA's latest filing, from $8.5 million in the prior quarter.
- Over five years, Long-Term Deferred Tax peaked at $9.9 million in Q4 2022 and troughed at $5.8 million in Q4 2020.
- A 3-year average of $8.1 million and a median of $8.5 million in 2021 frame the typical range for Long-Term Deferred Tax.
- The sharpest annual moves came in 2021 and 2022: Long-Term Deferred Tax soared 45.71% in 2021, then grew 15.85% in 2022.
- Over 3 years, Long-Term Deferred Tax stood at $5.8 million in 2020, then surged by 45.71% to $8.5 million in 2021, then advanced by 15.85% to $9.9 million in 2022.
- According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $9.9 million, $8.5 million, and $5.8 million for Q4 2022, Q4 2021, and Q4 2020 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Genenta Science S.p.A | 25.03 Mn | -34.07 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 9.87 Mn |
| Dec 31, 2021 | 8.52 Mn |
| Dec 31, 2020 | 5.85 Mn |